[Specific immunotherapy using Alpha-Fraction-Retard-D. pteronyssinus. Double-blind study in asthma].
A multicenter, double blind clinical study on two homogeneous, treated and untreated groups, has allowed an objective appreciation of the results of specific immunotherapy using the alpha-fraction of D. pteronyssinus in asthma. A statistically significant difference was seen of the consumption of drugs in the treated group and in infants of less than 5 years (p = 0.047). Tolerance, evaluated as a function of local and secondary effects was excellent and comparable in the two groups.
Sabbah
A
A
Laboratoire d'Immuno-Allergologie, CHRU, Angers.
Bonnaud
F
F
Sonneville
A
A
Bonneau
J C
JC
Pinon
H
H
D000328:Adult; D000485:Allergens / Q000627:therapeutic use*; D000818:Animals; D039741:Antigens, Dermatophagoides; D001249:Asthma / Q000628:therapy*; D002675:Child, Preschool; D003888:Desensitization, Immunologic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008925:Mites / Q000276:immunology*
D000485:Allergens; D039741:Antigens, Dermatophagoides
Immunothérapie spécifique par l'alpha-fraction-retard-D. ptéronyssinus. Etude en double aveugle dans l'asthme.